8-K: Benitec Biopharma Reports Positive Interim Data for BB-301 Gene Therapy in OPMD Trial

Benitec Biopharma announced positive 180-day interim results from its Phase 1b/2a study of BB-301 gene therapy for OPMD, showing continued improvements in swallowing efficiency.

Summary

• Benitec Biopharma has released interim data from its Phase 1b/2a clinical trial for BB-301, a gene therapy for Oculopharyngeal Muscular Dystrophy (OPMD).
• The data focuses on the first subject treated with a low dose of BB-301, assessed at the 180-day timepoint.
• The study measured Total Pharyngeal Residue (TPR), the amount of food remaining in the throat after swallowing, and the Sydney Swallow Questionnaire (SSQ), a patient-reported outcome.
• Results showed that TPR remained meaningfully reduced at 180 days compared to pre-dose levels, with three of four food types showing lower TPR than at any point during the 9-month pre-dose observation period.
• The SSQ score also continued to decline, indicating improved swallowing function as reported by the subject, and was lower than at any point during the 9-month pre-dose period.
• Key Opinion Leaders have identified TPR and SSQ as central markers for evaluating the long-term clinical benefit of OPMD treatments.
• The second subject was dosed in February 2024, and the third is expected to be dosed in the third quarter of 2024.
• The company plans to provide additional analyses of the interim data at upcoming medical conferences and webcasts in the first quarter of 2025.

Sentiment

Score: 8

Explanation: The document presents positive interim clinical data with no serious adverse events, suggesting a promising outlook for the treatment. The sentiment is positive, but tempered by the early stage of the trial and the need for further data.

Positives

• The study showed continued durable improvements in swallowing efficiency at the 180-day timepoint.
• The Total Pharyngeal Residue (TPR) was reduced for the first subject across multiple food types.
• The Sydney Swallow Questionnaire (SSQ) scores showed a continued decline, indicating improved swallowing function.
• The results are consistent with the 90-day post-dose results, showing sustained improvement.
• No Serious Adverse Events (SAEs) were reported for the two subjects treated with the low dose of BB-301.
• The company is on track to dose the third subject in the third quarter of 2024.

Negatives

• Transient Grade 2 Gastroesophageal Reflux Disease (GERD) was reported previously in April 2024.

Risks

• The study is still in its early stages, and long-term efficacy and safety data are needed.
• The results are based on a single subject, and further data from additional subjects is required to confirm these findings.
• The company is dependent on its relationships with collaboration partners and other third parties.
• There are risks associated with the development and commercialization of gene therapies, including regulatory hurdles and market competition.
• The company's ability to satisfy its capital needs through increasing its revenue and obtaining additional financing is a risk.

Future Outlook

Benitec plans to provide additional analyses of the interim clinical study data at upcoming medical conferences and company-sponsored Research and Development-focused webcasts in the first quarter of calendar 2025. The company remains on track to report additional interim clinical study results (representing at least 6 or 12 months of follow-up for each study subject) on multiple patients in the first quarter of calendar 2025.

Management Comments

• Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec, stated that facilitating reductions in the quantities of solid food and liquid that remain in the throat post-swallow is believed to be a central indicator of improvement of swallowing and the reduction of the risk of aspiration in subjects suffering from OPMD.
• Jerel A. Banks also mentioned that the company is pleased to report continued positive interim clinical study data for Subject 1 in the investigational assessments deemed to be most critical for the evaluation of clinical benefit by the KOLs in the fields of OPMD research and patient care.

Industry Context

This announcement is significant in the context of the broader gene therapy field, particularly for rare diseases like OPMD, where there are limited effective treatments. The positive interim results could position Benitec as a key player in the development of novel genetic medicines for OPMD.

Comparison to Industry Standards

• The use of Total Pharyngeal Residue (TPR) and the Sydney Swallow Questionnaire (SSQ) as primary endpoints aligns with industry standards for assessing dysphagia in OPMD.
• Other companies developing treatments for OPMD include companies such as Avidity Biosciences and Sarepta Therapeutics, however, their approaches differ from Benitec's gene therapy approach.
• The reported improvements in TPR and SSQ scores are encouraging when compared to the natural progression of OPMD, which typically involves worsening dysphagia over time.
• The lack of serious adverse events is also a positive sign, as safety is a major concern in gene therapy trials.

Stakeholder Impact

• Shareholders may view the positive interim results favorably, potentially increasing the company's stock value.
• Patients with OPMD and their families may have increased hope for a potential treatment option.
• Employees of Benitec may be motivated by the positive progress of the clinical trial.
• The results could attract potential collaboration partners and investors.

Next Steps

• The company plans to dose the third subject in the third quarter of 2024.
• Benitec plans to provide additional analyses of the interim clinical study data at upcoming medical conferences and company-sponsored webcasts in the first quarter of calendar 2025.
• The company will continue to monitor the subjects and collect data at the 365-day post-dose assessment.

Key Dates

Keywords

OPMD, gene therapy, BB-301, clinical trial, dysphagia, swallowing, Total Pharyngeal Residue, Sydney Swallow Questionnaire, RNA interference, biotechnology